Shuttle Pharmaceuticals Faces Delisting Notice
Ticker: SHPH · Form: 8-K · Filed: Aug 26, 2024 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Aug 26, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-notice
TL;DR
Shuttle Pharma got a notice about failing listing rules - stock transfer incoming?
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. received a notice on August 21, 2024, indicating it failed to meet a continued listing rule or standard, potentially leading to a transfer of its listing. The company is incorporated in Delaware and its principal executive offices are located in Gaithersburg, MD.
Why It Matters
This notice suggests potential instability in the company's stock listing, which could impact investor confidence and trading liquidity.
Risk Assessment
Risk Level: high — A notice of failure to meet listing standards directly threatens the company's ability to remain listed on an exchange, posing a significant risk to its operations and stock value.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- August 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Gaithersburg, MD (location) — Principal executive offices
FAQ
What specific listing rule or standard did Shuttle Pharmaceuticals Holdings, Inc. fail to meet?
The filing states that the company received a notice of "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing" but does not specify the exact rule or standard that was violated.
What is the potential consequence of failing to meet the listing rule?
The consequence is a potential "Transfer of Listing," which implies the company may be moved to a different exchange or face delisting if the issue is not resolved.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated August 21, 2024.
Where are Shuttle Pharmaceuticals Holdings, Inc.'s principal executive offices located?
The principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Stats: 704 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-08-26 16:10:24
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-24-033876.txt ( ) — 228KB
- nasdaq-20240821.xsd (EX-101.SCH) — 3KB
- nasdaq-20240821_lab.xml (EX-101.LAB) — 33KB
- nasdaq-20240821_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 26, 2024 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. By: /s/ Timothy J. Lorber Name: Timothy J. Lorber Title: Chief Financial Officer 3